鞘内注射地塞米松作为FIRES的灭火器:12例发热感染相关癫痫综合征患者鞘内使用地塞米松的临床经验
本研究为国际多中心临床生物样本库的回顾性分析,纳入12例(10例儿童、2例成人)接受鞘内注射地塞米松(IT-DEX)治疗的NORSE(包括FIRES)患者,所有患者均符合FIRES。IT-DEX中位起始时间为难治性癫痫持续状态起病后20天,中位给药5剂,每剂中位剂量5 mg(0.21 mg/kg/剂)。临床医生报告83%的病例癫痫控制 perceived 获益,末次IT-DEX后中位5天撤除持续输注。细胞因子分析(4例系列脑脊液、2例系列血液)显示多数患者促炎标志物持续升高,IT-DEX后无显著变化;未报告不良事件。作者认为IT-DEX在终止难治性癫痫持续状态方面可能有益且似乎安全,但需进一步研究确认。
要点
- 12例FIRES患者接受鞘内注射地塞米松,中位给药5剂,每剂中位5 mg(0.21 mg/kg/剂),起始于难治性癫痫持续状态起病后中位20天。
- 临床医生报告83%的病例癫痫控制 perceived 获益,末次IT-DEX后中位5天撤除持续输注。
- 细胞因子分析(4例脑脊液、2例血液系列检测)显示多数患者促炎标志物持续升高,IT-DEX后无显著变化。
- 未报告不良事件;作者认为IT-DEX在FIRES患者中似乎安全。
- 作者结论:需进一步研究确认IT-DEX的安全性和有效性及其对长期结局(癫痫预防和功能恢复)的影响。
适用人群与场景
- 12例NORSE(包括FIRES)患者,均符合FIRES,其中10例儿童、2例成人,来自国际多中心临床生物样本库,接受IT-DEX作为治疗的一部分。
处置流程与药物剂量
- 鞘内注射地塞米松:中位给药5剂,每剂中位剂量5 mg(0.21 mg/kg/剂),起始于难治性癫痫持续状态起病后中位20天。
- 末次IT-DEX后中位5天撤除持续输注。
研究设计与关键结果
- 回顾性分析12例(10例儿童、2例成人)NORSE(包括FIRES)患者,均符合FIRES,接受IT-DEX治疗。
- 临床医生报告83%的病例癫痫控制 perceived 获益。
- 细胞因子分析(4例系列脑脊液、2例系列血液)显示多数患者促炎标志物持续升高,IT-DEX后无显著变化。
- 未报告不良事件。
证据类型、等级与局限
- 证据类型:国际多中心临床生物样本库的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为IT-DEX在终止难治性癫痫持续状态方面可能有益,且在FIRES患者中似乎安全。
- 作者建议需进一步研究确认IT-DEX的安全性和有效性及其对长期结局(包括癫痫预防和功能恢复)的影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: New-onset refractory status epilepticus (NORSE) is a devastating condition with high mortality and poor long-term outcomes. Febrile infection-related epilepsy syndrome (FIRES) is a subset of NORSE, preceded by fever. Intrathecal dexamethasone (IT-DEX) has emerged as a potential treatment, but few cases have been reported. This study aims to describe the use of IT-DEX in NORSE/FIRES, focusing on treatment logistics, dosing strategies, and patient outcomes.
METHODS: We conducted a retrospective analysis of 12 patients (10 children and 2 adults) with NORSE (including FIRES) enrolled in an international multicenter clinical biorepository who received IT-DEX as part of their treatment. Demographic and clinical data were extracted. IT-DEX pharmacological details and administration logistics were collected by contacting the primary investigators. A descriptive analysis was performed to evaluate treatment timing, dosage, and concurrent management, as well as clinical outcomes and cytokine profiles.
RESULTS: All patients qualified as FIRES. Patients were treated with a median of five doses of IT-DEX, starting a median of 20 days after refractory status epilepticus onset, with a median dose per infusion of 5 mg (0.21 mg/kg/dose). Clinicians reported a perceived favorable effect on seizure control in 83% of cases, with a median delay of 5 days to wean off continuous infusions after the last IT-DEX administration. Cytokine analysis (based on data from four patients with serial cerebrospinal fluid measurements and two patients with serial blood measurements) revealed persistently elevated levels of proinflammatory markers in most patients, with no significant changes following IT-DEX administration. No adverse effects were reported.
CONCLUSIONS: Most clinicians perceived a favorable effect of IT-DEX in refractory status epilepticus termination, and its use appears to be safe in patients with FIRES. This study provides a detailed description of administration logistics and dosing strategies from an international multicenter cohort. Additional studies are needed to confirm the safety and efficacy of IT-DEX and determine its impact on long-term outcomes including epilepsy prevention and functional recovery.
参考来源
- Farias-Moeller R, Hanin A, Ahsan S, et al. Intrathecal Dexamethasone as a FIRES Extinguisher: A 12-Patient Clinical Experience with Usage of Intrathecal Dexamethasone for Febrile Infection-Related Epilepsy Syndrome. Neurocrit Care. 2025. PMID: 40279013. doi:10.1007/s12028-025-02254-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。